|
Diabetes Medication Article
BYETTA - New Class of Diabetic Drug
Byetta is a drug derived from the saliva of the Gila monster lizard. I do know one person who is taking Byetta and has better control of her blood sugar levels. The medication has even decreased her appetite. That is a benefit for her since she is overweight.
Byetta (exenatide) is the first among a new class of diabetes drugs for Type 2 Diabetes called incretin mimetics -- synthetic medications that mimic action of a hormone that spurs insulin production after a person eats and blood sugar levels rise above a certain threshold.
Traditional diabetes drugs that promote insulin production do so even if glucose levels aren't high enough, which could cause hypoglycemia (dangerously low blood sugar).
Byetta, derived from the lizard's saliva, mimics that action of the human hormone GLP-1, which prompts the body to secrete insulin and is also thought to play a role in deciding when a person feels full. This is great because it almost acts like an appetite suppressant. Common side effects of the drug were nausea and decreased appetite.
Byetta is very unique and supposedly works in a different way than pills or insulin. By helping your body produce the right amount of insulin at the right time, Byetta helps take the guesswork out of type 2 diabetes.
Byetta is used in combination with Metformin (Glucophage) and Sulfonylurea like Amaryl® (glimepiride), Glucotrol® (glipizide), Micronase® (glyburide), and others.
Byetta is an injectable medication and comes in prefilled insulin pens where you just add a small needle and inject yourself.
The price tag is not small, but with the New Medicare Prescription Plan D, you can check out your prescription plan to see if this medication is covered.
If you are on oral diabetic medications and you are not controlled, this may be an option for you. Ask your doctor. It doesn't hurt to ask.
Please remember that primary physicians don't know everything. That is not saying they are not great doctors. No one person can know everything. Just like us nurses, some specialize in heart disease or diabetes or wound care, etc. That also applies to doctors.
If you have heart problems, you should probably get a referral to a cardiologist. The same thing with Diabetes. You may want to get a referral to an endocrinologist. Check with your primary doctor and see if a referral to an endocrinologist is right for you.
You can get more information about Byetta at http://www.byetta.com
F. Kuhn, RN
specializing in Diabetes
Diabetes Testing Center
Heart News Center
Hot Home Gym Reviews
The Secret Wisdom You Have Inside
Get Rid of Your Belly fat
Inhaled Insulin News
Inhaled insulin
IMPORTANT: Bing News RSS feed has moved!
SAN ANTONIO -- San Antonio diabetics are helping test the next generation of insulin. It’s a drug you inhale instead of inject. For patients who need blood sugar control, injected insulin is a wonder drug. Often, though, it doesn’t work fast ...
Read moreInhaled insulin shows promise for diabetics
GREENVILLE — Physicians East is looking for patients in the area to participate in clinical trials for a new diabetes treatment. AFREZZA, made by MannKind Corporation, is an insulin treatment that is inhaled at meal time to hopefully control ...
Read moreDiabetics needed to test inhaled insulin
The next generation of insulin is being tested right now, it's a drug you inhale instead of inject. For patients who need blood sugar control, injected insulin is wonder drug. But the problem is it doesn't work fast enough at meal time. Enter a trial ...
Read moreHealth Watch: Inhaled Insulin
The company’s lead pipeline candidate Afrezza is an inhaled insulin for the treatment of type I or type II diabetes. We remind investors that in January 2011, MannKind suffered a setback when the US Food and Drug Administration (:FDA ...
Read moreMannKind Treads the Neutral Path
The company's lead pipeline candidate Afrezza is an inhaled insulin for the treatment of type I or type II diabetes. We remind investors that in January 2011, MannKind suffered a setback when the US Food and Drug Administration (FDA) issued a second ...
Read moreMannKind Treads the Neutral Path - Analyst Blog
As I understand it, Exhubera (and other attempts at inhaled insulin) was a failure because of the inhaler device, not the drug itself. Whether Mannkind can pull this off is TBD, but I think they are on the right track. An interesting note ...
Read moreReasons to Remain Bullish on MannKind Corporation (NASDAQ:MNKD) in this Economic Backdrop
The book considers the pros and cons of inhaled insulin, insulin pumps, and continuous blood sugar monitors as well as how to make sense out of the many new insulin analogues and insulin mixtures, with special attention to a problem that many people who ...
Read moreDr. Bernstein's Big Book
If you're a newcomer to the company, MNKD has a few R&D irons in the fire. The lead drug candidate, however, is an inhaled-insulin called AFREZZA. In a nutshell, this treatment is designed to help Type 1 and Type 2 diabetes patients control hyperglycemia.
Read moreMannKind Corporation (MNKD) is Past the Point of No Return, For Better or Worse
Investors appeared to be taking advantage of the low price of the Valencia biotech’s beaten down stock, which fell 70 percent last year after regulators balked at approving its inhaled insulin product until the company agreed to additional ...
Read more